-
Company Insights
NewAir France – Digital Transformation Strategies
Air France-KLM Digital Transformation Strategies Overview Air France has been focusing on using artificial intelligence, the Internet of Things (IoT), cloud-based mobile applications, big data, and drones to digitally transform its operations. The annual ICT spending of Air France was estimated at $911.8 million for 2023. A major share of this spending is earmarked for acquiring software, hardware, and ICT services from vendors. Air France-KLM is an international airline group specializing in air passenger transport, cargo transport, and aircraft maintenance....
-
Product Insights
NewPTCA Drug Coated Balloon (DCB) Catheters Pipeline by Development Stages, Segments, Region and Countries, Regulatory Path and Key Companies
PTCA Drug Coated Balloon (DCB) Catheters Pipeline Market Report Overview A Drug Coated Balloon (DCB) Catheter is an anti-restenotic drug coated PTCA balloon catheter intended to prevent re-narrowing of the coronary arteries. The PTCA Drug Coated Balloon (DCB) Catheters pipeline market research report provides a comprehensive understanding of the pipeline products along with their comparative analysis at various stages of development. The report also includes information about the territories wherein the clinical trials are in progress, the regulatory paths followed...
-
Product Insights
NewPTA Peripheral DCB Catheters Pipeline by Development Stages, Segments, Region and Countries, Regulatory Path and Key Companies
PTA Peripheral DCB Catheters Pipeline Market Report Overview A PTA Peripheral DCB Catheter is a drug-coated percutaneous transluminal angioplasty (PTA) balloon intended to prevent restenosis or restenosis of the peripheral arteries. PTA Peripheral DCB catheters provide fast, short-term, homogenous, local drug delivery to the vessel wall while preserving the anatomy of the vessel, promoting enhanced vessel healing, and reducing the need for prolonged dual antiplatelet therapy. They can be used to treat native and in-stent restenosis (ISR), bifurcations, small vessels,...
-
Product Insights
Likelihood of Approval and Phase Transition Success Rate Model – Fusion Protein To Agonize CD261 And CD262 For Oncology in Relapsed Multiple Myeloma
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Fusion Protein To Agonize CD261 And CD262 For Oncology in Relapsed Multiple Myeloma report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Fusion Protein To...
-
Product Insights
Likelihood of Approval and Phase Transition Success Rate Model – Fusion Protein To Agonize CD261 And CD262 For Oncology in Refractory Multiple Myeloma
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Fusion Protein To Agonize CD261 And CD262 For Oncology in Refractory Multiple Myeloma report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Fusion Protein To...
-
Product Insights
Likelihood of Approval and Phase Transition Success Rate Model – Eftozanermin Alfa in Relapsed Multiple Myeloma
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Eftozanermin Alfa in Relapsed Multiple Myeloma report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Eftozanermin Alfa in Relapsed Multiple Myeloma Drug Details: Eftozanermin alfa...
-
Product Insights
Likelihood of Approval and Phase Transition Success Rate Model – Eftozanermin Alfa in Diffuse Large B-Cell Lymphoma
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Eftozanermin Alfa in Diffuse Large B-Cell Lymphoma report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Eftozanermin Alfa in Diffuse Large B-Cell Lymphoma Drug Details:...
-
Product Insights
Mountain Trail Solar PV Park, US
Mountain Trail Solar PV Park is proposed to be developed in Pennsylvania, United States. Empower your strategies with our Mountain Trail Solar PV Park report and make more profitable business decisions. Note: This is an on-demand report that will be delivered upon request. The report will be delivered within 2 to 3 business day of the purchase, excluding weekends and holidays. Certain sections of the report may be removed or altered based on data availability and relevance. Reasons to buy...